Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM1036 for Low Anterior Resection Syndrome
NCT05527301Phase 2Not yet recruiting
- Sponsor
- HEM Pharma Inc.
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Live Biotherapeutic Products
01
Overview
A Phase 2 trial of limosilactobacillus fermentum in low anterior resection syndrome (LARS), sponsored by HEM Pharma Inc.. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
limosilactobacillus fermentum
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on NCT05527301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527301.